Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Site-specific immune response to implanted gliomas.

M A Proescholdt1, M J Merrill, B Ikejiri

  • 1Surgical Neurology and Neuroimmunology Branches, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892-1414, USA.

Journal of Neurosurgery
|January 5, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neuropathology in a case of episodic ataxia type 4.

Neuropathology and applied neurobiology·2015
Same author

Association between frontal sinus development and persistent metopic suture.

Folia morphologica·2014
Same author

Allelic deletions on chromosome-17 and mutations in the p53 gene in tumors metastatic to brain.

International journal of oncology·2011
Same author

Correlation of end-tidal CO2 with transcranial Doppler flow velocity is decreased during chemoregulation in delayed cerebral vasospasm after subarachnoid haemorrhage--results of a pilot study.

Acta neurochirurgica. Supplement·2008
Same author

A comparison of immunometric and radioimmunoassay measurement of ACTH for the differential diagnosis of Cushing's syndrome.

Journal of endocrinological investigation·2007
Same author

Image-guided, direct convective delivery of glucocerebrosidase for neuronopathic Gaucher disease.

Neurology·2006
Same journal

Extent of resection as an independent predictor of survival for patients with glioblastoma as defined by the new WHO 2021 classification.

Journal of neurosurgery·2026
Same journal

Surgical treatment of schwannomas around the tarsal tunnel: a case series of 40 patients and systematic review of the literature.

Journal of neurosurgery·2026
Same journal

Direct targeting for focused ultrasound thalamotomy in the treatment of movement disorders.

Journal of neurosurgery·2026
Same journal

Development and internal validation of the Meningioma Functional Outcome Risk and Counseling Estimator 6 score, a point-based prognostic tool for predicting 6-week functional independence after intracranial meningioma resection.

Journal of neurosurgery·2026
Same journal

Connectional anatomy of the cerebellum: dentate nucleus and cerebellar peduncles from a surgical perspective.

Journal of neurosurgery·2026
Same journal

Press releases in neurosurgery: is scientific accuracy compromised in public reporting of neurosurgery research?

Journal of neurosurgery·2026
See all related articles

Early glioblastoma growth in the brain shows reduced immune cell markers and infiltration, suggesting immune privilege. These differences diminish as tumors grow, potentially due to blood-brain barrier changes, while lymphocytes show anergy.

Area of Science:

  • Neuro-oncology
  • Immunology
  • Cancer Biology

Background:

  • Immunotherapy for glioblastoma (GBM) has historically failed.
  • The brain's unique immunological environment, including the blood-brain barrier (BBB), may hinder anti-tumor immune responses.
  • The authors investigate if the BBB protects early-stage brain tumors from immune surveillance.

Purpose of the Study:

  • To compare the host immune response to glioma in the brain versus subcutaneous tissue during early tumor development.
  • To elucidate the immunological characteristics of early tumor growth within the brain's microenvironment.

Main Methods:

  • Gliomas were implanted in the brain and subcutaneously in rats.
  • Tumor samples were analyzed immunohistochemically for Major Histocompatibility Complex (MHC) Class I & II molecules, CD4/CD8 lymphocytes, B7-1 costimulatory molecule expression, and lymphocyte apoptosis over 7 days.

Related Experiment Videos

Main Results:

  • Brain tumors exhibited significantly lower MHC Class II expression and lymphocytic infiltration on Days 3-4 post-implantation compared to subcutaneous tumors (p < 0.05).
  • These differences normalized after Day 5, possibly due to BBB disruption by tumor growth.
  • Microglia were identified as the primary MHC Class II-expressing cells in brain tumors.
  • Both tumor types showed minimal B7-1 expression and significant lymphocyte apoptosis, indicating clonal anergy.

Conclusions:

  • The brain's early immune privilege, characterized by low MHC Class II and reduced lymphocytic infiltration, protects nascent gliomas.
  • Tumor-induced BBB disruption may alter this immune privilege over time.
  • Glioma-infiltrating lymphocytes exhibit clonal anergy irrespective of tumor location, suggesting intrinsic tumor factors contribute to immune evasion.